CClinicalTrials.gg
WithdrawnNCT00733967Updated Jul 27, 2012

Varenicline-Methamphetamine Interaction Study (2008)

A Phase 1 interventional study of Varenicline and Placebo in Methamphetamine Dependence, Substance Abuse and Methamphetamine Abuse, sponsored by Baylor College of Medicine. Withdrawn. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2012-07-27.

Sponsored by Baylor College of Medicine · Phase 1 and Interventional

Why this study was withdrawn
No longer active
Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary aim of the study is to determine the safety and tolerability of treatment with Varenicline in methamphetamine-dependent volunteers. The investigators also seek to determine the effects of treatment with Varenicline, as compared to placebo, on craving for methamphetamine or cigarettes following exposure to methamphetamine and smoking cues, respectively. The effects of treatment with Varenicline, as compared to placebo, on subjective effects produced by administration of methamphetamine or placebo will be attempted to be determined. Lastly, the investigators hope to determine the effects of treatment with Varenicline, as compared to placebo, on reinforcing effects produced by administration of methamphetamine or placebo.

Read the detailed description

See Brief Summary

02

Conditions studied

  • Methamphetamine Dependence
  • Substance Abuse
  • Methamphetamine Abuse

Keywords

  • Methamphetamine
  • Chantix
  • Varenicline
03

In context

Substance-Related Disorders

2,124 studies on the registry are indexed under Substance-Related Disorders; 393 are open to participants now.

Browse Substance-Related Disorders studies →

Lead sponsor

Baylor College of Medicine is the lead sponsor of 734 studies on the registry; 110 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 44 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • English speaking volunteers who are not seeking treatment at the time of the study
  • Be between 18-55 years of age
  • Meet DSM-IV criteria for MA dependence
  • Must be cigarette smokers, defined as smoking 10 or more cigarettes per day by self-report
  • Have a self-reported history of using MA by the smoked or IV route and provide at least one MA-positive urine prior to admission
  • Have vital signs as follows: resting pulse between 50 and 90 bpm, blood pressures between 105-150 mm Hg systolic and 45-90 mm HG diastolic; this criterion must be met within 2 days of admission
  • Have hematology and chemistry laboratory tests that are within normal (+/- 10%) limits with the following exceptions: a) liver function tests (total Bilirubin, ALT, AST, and alkaline phosphatase) \< 3 x the upper limit of normal, and b) kidney function tests (creatinine and BUN) \< 2 x the upper limit of normal
  • Have a baseline EKG that demonstrates normal sinus rhythm, normal conduction (including QTc), and no clinically significant arrhythmias
  • Have a medical history and brief physical examination demonstrating no clinically significant contradictions for study participation, in the judgment of the admitting physician or nurse practitioner and the principal investigator

Exclusion criteria

Exclusion Criteria:

  • Have any history or evidence suggestive of seizure disorder or brain injury
  • Have any previous medically adverse reaction to MA, including loss of consciousness, chest pain, or epileptic seizure
  • Have neurological or psychiatric disorders, such as: psychosis, bipolar illness or major depression as assessed by MINI; organic brain disease or dementia assessed by clinical interview; history of any psychiatric disorder which would require ongoing treatment or which would make study compliance difficult; history of suicide attempts within the past three months assessed by MINI and/or current suicidal ideation/plan as assessed by MINI
  • Have evidence of clinically significant heart disease or hypertension, as determined by the PI
  • Have a family history in first-degree relatives of early cardiovascular morbidity or mortality, as determined by the PI
  • Have evidence of untreated or unstable medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease
  • Have HIV and are currently symptomatic, have a diagnosis of AIDS, or are receiving antiretroviral medication
  • Be pregnant or nursing. Other females must either be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal) or be using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide). All females must provide negative pregnancy urine tests before study entry, upon hospital admission, and at the end of study participation
  • Have asthma or currently use alpha or beta agonists, theophylline, or other sympathomimetics
  • Have any other illness, condition, or use of psychotropic medications, which in the opinion of the PI and/or the admitting physician or nurse practitioner would preclude safe and/or successful completion of the study
05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching oral placebo capsules as control.

    Drug: Placebo

  • Active comparator
    Varenicline

    See assigned interventions.

    Drug: Varenicline

Interventions

  • DrugVarenicline

    Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.

    Also known as: Chantix

  • DrugPlacebo

    Matching oral placebo capsules as control.

    Also known as: Sugar pill

06

What researchers measure

Primary outcomes

  1. Effects of varenicline and methamphetamine on cardiovascular measures.

    The safety of MA administration during treatment will be assessed by reporting of adverse events (AEs), and using ECG recording, and heart rate and blood pressure measurements. Digital 12-lead EKG will also be recorded prior to randomization. Blood pressure and heart rate will be measured from 15 min prior to MA or placebo dosing until 2 h after dosing. In addition, heart rate and blood pressure will be assessed throughout the inpatient portion of the protocol.

Secondary outcomes

  1. Effects of varenicline and methamphetamine on subjective measures

    Efficacy will be assessed by measuring effects of treatment on subjective and reinforcing effects produced by administration of MA and craving produced by exposure to drug cues. Other diagnostic measures and assessment instruments will be used to further characterize the study population.

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00733967
Lead sponsor
Baylor College of Medicine
Collaborators
National Institute on Drug Abuse (NIDA)
Responsible party
Richard De La Garza (Associate Professor, Baylor College of Medicine) — Principal investigator
First posted
Aug 13, 2008
Start date
Jan 2008
Primary completion
Aug 2008
Completion
Aug 2008
Last update
Jul 27, 2012

Study contacts

Richard De La Garza, II, PhD
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion